Moxifloxacin hydrochloride

Moxifloxacin hydrochloride is an antibacterial prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain bacterial infections, including community-acquired pneumonia, acute worsening of chronic bronchitis, acute sinus infections, plague, and skin and abdominal infections.Community-acquired pneumonia, a bacterial respiratory infection, can be an opportunistic infection (OI) of HIV. An OI is an infection that occurs more frequently or is more severe in people with weakened immune systems —including people with HIV—than in people with healthy immune systems. It is grouped under the following drug class(es): Fluoroquinolones, Quinolones and Topoisomerase inhibitors. Its therapeutic use is listed as ophthalmic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Vigamox, Moxeza, Bay-12-8039 and Moxivig. Its PubChem CID is 101526.

CAS No 186826-86-8
Molecular Formula C21H25ClFN3O4
Molecular Weight 437.90 g/mol
Synonyms 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride

Frequently Asked Questions